🎉 M&A multiples are live!
Check it out!

Day One Biopharmaceutical Valuation Multiples

Discover revenue and EBITDA valuation multiples for Day One Biopharmaceutical and other public comps.

See Day One Biopharmaceutical Valuation Multiples

Day One Biopharmaceutical Overview

About Day One Biopharmaceutical

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.


Founded

2018

HQ

United States of America
Employees

155

Website

dayonebio.com

Financials

LTM Revenue $126M

LTM EBITDA -$192M

EV

$659M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Day One Biopharmaceutical Financials

Day One Biopharmaceutical has a last 12-month revenue of $126M and a last 12-month EBITDA of -$192M.

In the most recent fiscal year, Day One Biopharmaceutical achieved revenue of n/a and an EBITDA of -$206M.

Day One Biopharmaceutical expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Day One Biopharmaceutical valuation multiples based on analyst estimates

Day One Biopharmaceutical P&L

FY 2022 FY 2023 FY 2024 LTM NTM
Revenue n/a n/a $122M $126M XXX
Gross Profit n/a n/a n/a XXX XXX
Gross Margin NaN% NaN% NaN% XXX XXX
EBITDA -$146M -$206M -$199M -$192M XXX
EBITDA Margin -Infinity% -Infinity% -163% -152% XXX
Net Profit -$70.6M -$142M -$189M XXX XXX
Net Margin -Infinity% -Infinity% -155% XXX XXX
Net Debt n/a n/a n/a XXX XXX

Financial data powered by Morningstar, Inc.

Day One Biopharmaceutical Stock Performance

As of February 7, 2025, Day One Biopharmaceutical's stock price is $12.

Day One Biopharmaceutical has current market cap of $1.2B, and EV of $659M.

See Day One Biopharmaceutical trading valuation data

Day One Biopharmaceutical Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
$659M $1.2B XXX XXX XXX XXX $-0.77

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Day One Biopharmaceutical Valuation Multiples

As of February 7, 2025, Day One Biopharmaceutical has market cap of $1.2B and EV of $659M.

Day One Biopharmaceutical's trades at 5.2x LTM EV/Revenue multiple, and -3.4x LTM EBITDA.

Analysts estimate Day One Biopharmaceutical's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Day One Biopharmaceutical and 10K+ public comps

Day One Biopharmaceutical Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV $659M XXX XXX XXX
EV/Revenue 5.4x XXX XXX XXX
EV/EBITDA -3.3x XXX XXX XXX
P/E -19.4x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -5.2x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Day One Biopharmaceutical Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Day One Biopharmaceutical Valuation Multiples

Day One Biopharmaceutical's NTM/LTM revenue growth is 42%

Day One Biopharmaceutical's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.3M for the same period.

Over next 12 months, Day One Biopharmaceutical's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Day One Biopharmaceutical's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Day One Biopharmaceutical and other 10K+ public comps

Day One Biopharmaceutical Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth Infinity% XXX XXX XXX XXX
EBITDA Margin -163% XXX XXX XXX XXX
EBITDA Growth -3% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -122% XXX XXX XXX XXX
Revenue per Employee n/a XXX XXX XXX XXX
Opex per Employee $1.3M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue n/a XXX XXX XXX XXX
R&D Expenses to Revenue n/a XXX XXX XXX XXX
Opex to Revenue n/a XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Medical Devices
Consumer SaaS
Streaming Platforms
AdTech Software
Climate Tech
GRC Software
Developer Tools

Day One Biopharmaceutical Public Comps

See valuation multiples for Day One Biopharmaceutical public comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Day One Biopharmaceutical M&A and Investment Activity

Day One Biopharmaceutical acquired  XXX companies to date.

Last acquisition by Day One Biopharmaceutical was  XXXXXXXX, XXXXX XXXXX XXXXXX . Day One Biopharmaceutical acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Day One Biopharmaceutical

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Day One Biopharmaceutical

When was Day One Biopharmaceutical founded? Day One Biopharmaceutical was founded in 2018.
Where is Day One Biopharmaceutical headquartered? Day One Biopharmaceutical is headquartered in United States of America.
How many employees does Day One Biopharmaceutical have? As of today, Day One Biopharmaceutical has 155 employees.
Who is the CEO of Day One Biopharmaceutical? Day One Biopharmaceutical's CEO is Dr. Jeremy Bender.
Is Day One Biopharmaceutical publicy listed? Yes, Day One Biopharmaceutical is a public company listed on NAS.
What is the stock symbol of Day One Biopharmaceutical? Day One Biopharmaceutical trades under DAWN ticker.
When did Day One Biopharmaceutical go public? Day One Biopharmaceutical went public in 2021.
Who are competitors of Day One Biopharmaceutical? Similar companies to Day One Biopharmaceutical include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Day One Biopharmaceutical? Day One Biopharmaceutical's current market cap is $1.2B
What is the current revenue of Day One Biopharmaceutical? Day One Biopharmaceutical's last 12-month revenue is $126M.
What is the current EBITDA of Day One Biopharmaceutical? Day One Biopharmaceutical's last 12-month EBITDA is -$192M.
What is the current EV/Revenue multiple of Day One Biopharmaceutical? Current revenue multiple of Day One Biopharmaceutical is 5.2x.
What is the current EV/EBITDA multiple of Day One Biopharmaceutical? Current EBITDA multiple of Day One Biopharmaceutical is -3.4x.
Is Day One Biopharmaceutical profitable? Yes, Day One Biopharmaceutical is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.